Can emerging biomarkers of myocardial remodelling identify asymptomatic hypertensive patients at risk for diastolic dysfunction and diastolic heart failure? - Wikidata - wikimedia - TriplyDB

Can emerging biomarkers of myocardial remodelling identify asymptomatic hypertensive patients at risk for diastolic dysfunction and diastolic heart failure?

Can emerging biomarkers of myocardial remodelling identify asymptomatic hypertensive patients at risk for diastolic dysfunction and diastolic heart failure?

http://www.wikidata.org/entity/Q49106557

about

Heart failure with preserved ejection fraction: emerging drug strategies The role of titin and extracellular matrix remodelling in heart failure with preserved ejection fraction Exercise intolerance in heart failure with preserved ejection fraction: more than a heart problem Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies Emerging risk biomarkers in cardiovascular diseases and disorders Can biomarkers help to diagnose early heart failure with preserved ejection fraction?Should there be sex-specific criteria for the diagnosis and treatment of heart failure?Shared biomarkers between female diastolic heart failure and pre-eclampsia: a systematic review and meta-analysis.Targeting Endothelial Function to Treat Heart Failure with Preserved Ejection Fraction: The Promise of Exercise Training.Heart failure with preserved ejection fraction: molecular pathways of the aging myocardium Investigating the potential role of TRPA1 in locomotion and cardiovascular control during hypertension.Modest elevation in BNP in asymptomatic hypertensive patients reflects sub-clinical cardiac remodeling, inflammation and extracellular matrix changes.Inflammation and oxidative stress caused by nitric oxide synthase uncoupling might lead to left ventricular diastolic and systolic dysfunction in patients with hypertension.Incremental prognostic significance of the elevated levels of pentraxin 3 in patients with heart failure with normal left ventricular ejection fraction.Lipids, blood pressure, kidney - what was new in 2011?Aldosterone and cardiovascular disease: the heart of the matter.Influencing factors on cardiac structure and function beyond glycemic control in patients with type 2 diabetes mellitus.Myocardial dysfunction occurs prior to changes in ventricular geometry in mice with chronic kidney disease (CKD)Red cell distribution width and mortality in acute heart failure patients with preserved and reduced ejection fraction.Heart failure with preserved ejection fraction in the elderly: scope of the problem.Heart failure highlights in 2011.Molecular and cellular basis for diastolic dysfunction.Insights into the activity, differential expression, mutual regulation, and functions of matrix metalloproteinases and a disintegrin and metalloproteinases in hypertension and cardiac disease.Galectin-3 in heart failure with preserved ejection fraction.Biomarkers of heart failure with normal ejection fraction: a systematic review.Role of inflammation in the pathogenesis of heart failure with preserved ejection fraction and its potential as a therapeutic target.Circulating biomarkers in patients with heart failure and preserved ejection fraction.Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes.Heart failure with preserved ejection fraction: Defining the function of ROS and NO.Role of biomarkers in cardiac structure phenotyping in heart failure with preserved ejection fraction: critical appraisal and practical use.Heart Failure with Preserved Ejection Fraction in Older Adults.Connecting heart failure with preserved ejection fraction and renal dysfunction: the role of endothelial dysfunction and inflammation.Management of Heart Failure with Preserved Ejection Fraction: Current Challenges and Future Directions.Myocardial reverse remodeling: how far can we rewind?Attenuation of monocyte chemotaxis--a novel anti-inflammatory mechanism of action for the cardio-protective hormone B-type natriuretic peptide.Diastolic heart failure: What we still don't know. Looking for new concepts, diagnostic approaches, and the role of comorbidities.Cardiosphere-derived cells reverse heart failure with preserved ejection fraction (HFpEF) in rats by decreasing fibrosis and inflammation.Biomarker Profiles in Heart Failure Patients With Preserved and Reduced Ejection Fraction.Prognosis of new-onset heart failure outpatients and collagen biomarkers.Diagnostic and prognostic value of osteopontin in patients with acute congestive heart failure.

P2860

Q24595118-836E2285-E31B-4799-BD9C-B6598FC09566 Q26765101-5FC22F99-2F16-4CD5-BFF8-1D30A3F7D89B Q26991985-A0C9C9A1-148E-4BA7-80B4-ACA9839C0BEA Q27000263-F6AE16D6-1CEF-4243-88AF-D9793B647692 Q28081614-C0E2E080-6C14-43E5-B50A-FA339307F68D Q28087822-925FB8E2-67D1-47CC-8936-6484200D1BFE Q30442043-FB244871-BFEB-41FB-9E91-7DCF2428644C Q33577443-9AA778F7-191C-4214-B6A7-8993609592EE Q33863759-699E729D-7646-4844-A72C-1953F954D812 Q33889242-AAAA0776-BFB2-4895-BAA8-E07B682F3F87 Q34292579-2368B1E8-ACD3-4F33-A203-6CB9400B090B Q34477882-537380FF-099D-4AE3-82C1-BB6C868E371D Q35019654-B1EA1483-CCDF-48E8-B399-10C0A232103A Q35026270-02FE9DA3-7848-4A58-804C-C981CB9A8D02 Q35691396-B84771D1-52FF-44EE-81A4-379E8291119E Q36494721-FC235D15-6223-48D5-B4A6-6A21DAF8B43F Q36688287-FB7954FE-95E8-4076-9622-BFBB1F7119F2 Q36773711-EBB1C7C0-4E36-4D59-B999-54D427CAB753 Q37357329-AC52669C-E2ED-45FD-9F20-FB5F28095CCB Q37633991-816F8623-F607-44A4-9C52-DB7013D8FE0A Q38035177-59C67249-C714-4DD6-9715-07302BF3EBD4 Q38038531-CE5B5BBD-5C1D-40FE-8D36-F76BFCD2B26E Q38061567-8A2709E4-EE65-4479-B61A-D6384F03AD07 Q38104695-A9E9432B-0B6D-43D3-8E8E-CDA01A516964 Q38120919-35004516-FC7E-4518-B81A-BF81C36BE891 Q38134311-6A271912-54A1-4210-8D53-FAFB8483F6EC Q38152289-36A6D746-2A50-400D-B859-A9FD1CCD1258 Q38427211-1C00FBD7-B041-4DF5-A69F-DB9DFF462FD9 Q38482322-4539FCCA-B118-4640-9172-D69755D33009 Q38614176-1A1DEAAF-A130-419B-B41D-8CBF062F0283 Q38672337-FD1C15FF-5BB6-49B6-A3D8-8F1BFFE3238A Q38727741-5822B3A5-2537-4AD7-8085-9276EBB08D89 Q38743215-1EFA2560-0FA7-4A22-9765-63DA352DB57F Q38780883-C44B6BB0-9A30-4E99-A9C9-5F4154EE2C15 Q39159036-2DE3EC32-D3E3-4CF1-BD80-A3CB35AB6AB2 Q39514776-99DD8EB7-1CB9-477C-8656-AA1F9C5C5F6C Q40286144-7926CA0E-50B8-4478-9D2A-3BADB9045F7B Q41165768-8253850C-CED8-4375-A3A7-C1095B98F92F Q41666901-86F14577-E870-4D42-B0E1-DE241BCA6EA6 Q43807471-73724347-CFBA-4F42-AA54-3B642143E713

P2860

Can emerging biomarkers of myocardial remodelling identify asymptomatic hypertensive patients at risk for diastolic dysfunction and diastolic heart failure?

http://www.wikidata.org/entity/Q49106557

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh

2011年學術文章

@zh-hant

name

Can emerging biomarkers of myo ...... n and diastolic heart failure?

@en

Can emerging biomarkers of myo ...... n and diastolic heart failure?

@nl

type

label

Can emerging biomarkers of myo ...... n and diastolic heart failure?

@en

Can emerging biomarkers of myo ...... n and diastolic heart failure?

@nl

prefLabel

Can emerging biomarkers of myo ...... n and diastolic heart failure?

@en

Can emerging biomarkers of myo ...... n and diastolic heart failure?

@nl

P1433

Q49106557-6323746F-4FFD-4240-8A5D-B80DC86BB62D

P1476

Q49106557-0A230D56-B12A-43BA-8BA1-EB272CB0CE77

P2093

Q49106557-58950E7A-61C6-4C4E-AF2A-0A265F5BE8CE

Q49106557-5E051A7D-C6B2-4F79-A9CE-BBAE88453245

Q49106557-5F6F4B71-33AF-4E7A-8225-5AE82A4357BC

Q49106557-7B5A3399-E8D0-4339-A2C1-5AC2F536B515

Q49106557-99BEF8E8-4323-4D5F-8C87-07857B6F5E28

Q49106557-A4895CF7-62D1-4406-8403-AF4EC03CF71B

Q49106557-B34E8222-472A-4762-A52C-2EED4FA67D90

Q49106557-EB80E157-C2E9-422F-A22D-3A041CCD7D7F

Q49106557-EFF3943A-1AA0-48B4-B93A-15C56960DF3D

Q49106557-F28B67D2-CFF1-436D-B714-7DC27583E5C2

P2860

Q49106557-0C2F6648-3D74-47B4-A876-B820B09A55CB

Q49106557-2ED5EA55-23F2-45F5-B61B-B2DA2F925780

Q49106557-3AB4D198-2A7A-4BC9-BDBF-12E3BA5E668B

Q49106557-3F677D31-D648-4B6D-AB44-C21058BE1E04

Q49106557-48E48F8D-97F7-4A94-9DAF-00A2F11AFAC2

Q49106557-4B5C8554-3C33-4233-9028-371AAFD8E462

Q49106557-4EE54292-129E-4E64-81BE-8E7D4EE8AB68

Q49106557-56D871CB-B18D-4ADA-AC4D-424FD9DBBFC9

Q49106557-61689260-1001-41B6-A73A-5FD055958C1D

Q49106557-81E832E4-9176-4F2B-AFC2-DD9A7B5DC6F1

P304

Q49106557-A4A419DD-62DC-419D-BA53-1D00A9776FEE

P31

Q49106557-06F899CA-3025-4BE7-8EA1-ACDBCA466697

P356

Q49106557-077D3F3B-6EBC-45E3-85EF-3944C2B6607E

P433

Q49106557-A6FF54BB-D24F-40EE-9FFD-D1DEADB8F369

P478

Q49106557-A19455A5-E7D0-4FEF-A817-11426A6E3934

P577

Q49106557-6AF01FE5-2370-43F0-938C-0571A6B34356

P5875

Q49106557-6782A905-7901-41B3-B90B-F36B7F5BC841

P698

Q49106557-8B52322E-55E0-4A4F-8F81-C70C93DE32EA

P921

Q49106557-2C5B8022-30BB-4F23-961D-FEE4835DA9CD

Q49106557-5FA42581-4726-4C37-A658-8055E5475D5C

Q49106557-936304FE-DA28-4991-A7F6-9F09FE947ABC

Q49106557-CDFF6ED1-15D0-4608-AB65-84C228A33EF0

P356

P1433

European Journal of Heart Failure

P1476

Can emerging biomarkers of myo ...... n and diastolic heart failure?

@en

P2093

Aftab Jan

http://www.w3.org/2001/XMLSchema#string

Chris J Watson

http://www.w3.org/2001/XMLSchema#string

Dermot Phelan

http://www.w3.org/2001/XMLSchema#string

George Mak

http://www.w3.org/2001/XMLSchema#string

John A Baugh

http://www.w3.org/2001/XMLSchema#string

Kenneth M McDonald

http://www.w3.org/2001/XMLSchema#string

Mark T Ledwidge

http://www.w3.org/2001/XMLSchema#string

Patrick Collier

http://www.w3.org/2001/XMLSchema#string

Ramon Martos

http://www.w3.org/2001/XMLSchema#string

Victor Voon

http://www.w3.org/2001/XMLSchema#string

P2860

Spironolactone in congestive heart failure.

Interleukin 6 mediates myocardial fibrosis, concentric hypertrophy, and diastolic dysfunction in rats.

Association between elevated fibrosis markers and heart failure in the elderly: the cardiovascular health study

Inflammatory markers and incident heart failure risk in older adults: the Health ABC (Health, Aging, and Body Composition) study.

The biologic variability of B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide in stable heart failure patients.

Diagnosis of heart failure with preserved ejection fraction: improved accuracy with the use of markers of collagen turnover.

Understanding the 'epidemic of heart failure': a systematic review of trends in determinants of heart failure.

A biochemical model of matrix metalloproteinase 9 activation and inhibition.

Toward the biochemical assessment of myocardial fibrosis in hypertensive patients.

Relation of circulating markers of fibrosis and progression of left and right ventricular dysfunction in hypertensive patients with heart failure.

P304

1087-1095

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/EURJHF/HFR079

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P577

2011-06-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51457943

http://www.w3.org/2001/XMLSchema#string

P698

21719449

http://www.w3.org/2001/XMLSchema#string

P921